We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JBL icon
551
Jabil
JBL
$30.4B
– –
-19,662
Closed -$2.14M
JWN
552
DELISTED
Nordstrom
JWN
– –
-42,747
Closed -$907K
OPLN
553
Openlane
OPLN
$4.29B
– –
-14,062
Closed -$233K
KKR icon
554
KKR & Co
KKR
$89.6B
– –
-6,567
Closed -$691K
KMPR icon
555
Kemper
KMPR
$1.8B
– –
-4,220
Closed -$250K
KMT icon
556
Kennametal
KMT
$2.52B
– –
-51,081
Closed -$1.2M
KMX icon
557
CarMax
KMX
$8.43B
– –
-3,881
Closed -$285K
KTOS icon
558
Kratos Defense & Security Solutions
KTOS
$8.38B
– –
-48,909
Closed -$979K
LGND icon
559
Ligand Pharmaceuticals
LGND
$5.82B
– –
-7,916
Closed -$667K
LMT icon
560
Lockheed Martin
LMT
$132B
– –
-642
Closed -$300K
LOPE icon
561
Grand Canyon Education
LOPE
$4.2B
– –
-3,308
Closed -$463K
LRCX icon
562
Lam Research
LRCX
$325B
– –
-8,030
Closed -$855K
LUNG icon
563
Pulmonx
LUNG
$52.8M
– –
-47,539
Closed -$301K
LYFT icon
564
Lyft
LYFT
$5.91B
– –
-32,516
Closed -$458K
MAN icon
565
ManpowerGroup
MAN
$2.62B
– –
-19,104
Closed -$1.33M
MASI
566
DELISTED
Masimo
MASI
– –
-1,848
Closed -$233K
MATW icon
567
Matthews International
MATW
$891M
– –
-57,723
Closed -$1.45M
MBC icon
568
MasterBrand
MBC
$1.07B
– –
-14,837
Closed -$218K
MCK icon
569
McKesson
MCK
$104B
– –
-902
Closed -$527K
MCY icon
570
Mercury Insurance
MCY
$6.04B
– –
-8,367
Closed -$445K
MELI icon
571
Mercado Libre
MELI
$95.2B
– –
-230
Closed -$378K
MFA
572
MFA Financial
MFA
$930M
– –
-52,748
Closed -$561K
MGEE icon
573
MGE Energy Inc
MGEE
$3.03B
– –
-9,585
Closed -$716K
MO icon
574
Altria Group
MO
$125B
– –
-20,214
Closed -$921K
MOH icon
575
Molina Healthcare
MOH
$10.4B
– –
-1,020
Closed -$303K
21 22
23
24 25

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.